The Carlyle Group is a global investment firm that specializes in various asset classes, including private equity, real estate, and credit. The company connects capital from investors with opportunities across a diverse range of industries and geographies, focusing on generating value through strategic investments and active management. With a strong emphasis on relationships, Carlyle collaborates with portfolio companies to enhance their growth prospects and operational efficiency, ultimately aiming to deliver attractive returns for its investors while maintaining a commitment to responsible investment practices. Read More
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. Under the terms of the amended agreement bluebird stockholders can elect to receive either (x) the original offer of $3.00 per share in cash plus a contingent value right (“CVR”) of $6.84 per share in cash payable upon achievement of a net sales milestone or (y) $5.00 per share in cash. The amended offer price provides an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR. Any shares tendered for which no election is made will receive the original consideration of $3.00 per share in cash and a contingent value right per share.
U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Reserve’s upcoming policy decision, with Chair Jerome Powell set to speak at 2:30 p.m. ET.
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) announced today that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received.
WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Socially Determined, a social risk analytics and solutions company leading the integration of health and social care, and Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial healthcare clients and the populations they serve, have partnered to deliver the power of data, raw computing, and AI analytics to help state healthcare agencies more accurately predict and target interventions that improve health outcomes for individuals and communities, and reduce program costs.
SoftBank has acquired Oracle-backed Ampere for $6.5 billion to strengthen its AI infrastructure strategy in the U.S., marking a major step in its broader push into Arm-based computing and large-scale AI development.
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutics and Ipsen, is expected to become CEO of bluebird upon closing. Carlyle and SK Capital will provide bluebird primary capital to scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.
Industry experts join board of seasoned advisors offering strategic counsel on healthcare trends and policy for the company and its portfolio of state, federal, and commercial clients
Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options
